Validation of International Society of Urological Pathology (ISUP) grading for prostatic adenocarcinoma in thin core biopsies using TROG 03.04 'RADAR' trial clinical data

Pathology. 2015 Oct;47(6):520-5. doi: 10.1097/PAT.0000000000000318.

Abstract

In 2014 a consensus conference convened by the International Society of Urological Pathology (ISUP) adopted amendments to the criteria for Gleason grading and scoring (GS) for prostatic adenocarcinoma. The meeting defined a modified grading system based on 5 grading categories (grade 1, GS 3+3; grade 2, GS 3+4; grade 3, GS 4+3; grade 4, GS 8; grade 5, GS 9-10). In this study we have evaluated the prognostic significance of ISUP grading in 496 patients enrolled in the TROG 03.04 RADAR Trial. There were 19 grade 1, 118 grade 2, 193 grade 3, 88 grade 4 and 79 grade 5 tumours in the series, with follow-up for a minimum of 6.5 years. On follow-up 76 patients experienced distant progression of disease, 171 prostate specific antigen (PSA) progression and 39 prostate cancer deaths. In contrast to the 2005 modified Gleason system (MGS), the hazards of the distant and PSA progression endpoints, relative to grade 2, were significantly greater for grades 3, 4 and 5 of the 2014 ISUP grading scheme. Comparison of predictive ability utilising Harrell's concordance index, showed 2014 ISUP grading to significantly out-perform 2005 MGS grading for each of the three clinical endpoints.

Publication types

  • Clinical Trial, Phase III
  • Randomized Controlled Trial
  • Validation Study

MeSH terms

  • Adenocarcinoma / mortality
  • Adenocarcinoma / pathology*
  • Adenocarcinoma / therapy
  • Adult
  • Aged
  • Androgen Antagonists / administration & dosage
  • Antineoplastic Agents / administration & dosage
  • Biopsy, Large-Core Needle
  • Chemoradiotherapy / methods
  • Consensus Development Conferences as Topic
  • Diphosphonates / administration & dosage
  • Humans
  • Imidazoles / administration & dosage
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Grading* / methods
  • Neoplasm Grading* / standards
  • Pathology, Surgical / standards
  • Proportional Hazards Models
  • Prostatic Neoplasms / mortality
  • Prostatic Neoplasms / pathology*
  • Prostatic Neoplasms / therapy
  • Societies, Medical
  • Urology / standards
  • Zoledronic Acid

Substances

  • Androgen Antagonists
  • Antineoplastic Agents
  • Diphosphonates
  • Imidazoles
  • Zoledronic Acid